331 related articles for article (PubMed ID: 29459361)
1. Comparison of Reduced-Dose Prasugrel and Standard-Dose Clopidogrel in Elderly Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Revascularization.
Savonitto S; Ferri LA; Piatti L; Grosseto D; Piovaccari G; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Rogacka R; Antonicelli R; Cesana BM; De Luca L; Ottani F; De Luca G; Piscione F; Moffa N; De Servi S;
Circulation; 2018 Jun; 137(23):2435-2445. PubMed ID: 29459361
[TBL] [Abstract][Full Text] [Related]
2. A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Ferri LA; Morici N; Grosseto D; Tortorella G; Bossi I; Sganzerla P; Cacucci M; Sibilio G; Tondi S; Toso A; Ferrario M; Gandolfo N; Ravera A; Mariani M; Corrada E; Di Ascenzo L; Petronio AS; Cavallini C; Moffa N; De Servi S; Savonitto S
Am Heart J; 2016 Nov; 181():101-106. PubMed ID: 27823681
[TBL] [Abstract][Full Text] [Related]
3. Time Course of Ischemic and Bleeding Burden in Elderly Patients With Acute Coronary Syndromes Randomized to Low-Dose Prasugrel or Clopidogrel.
Crimi G; Morici N; Ferrario M; Ferri LA; Piatti L; Grosseto D; Cacucci M; Mandurino Mirizzi A; Toso A; Piscione F; De Carlo M; Elia LR; Trimarco B; Bolognese L; Bovenzi FM; De Luca G; Savonitto S; De Servi S
J Am Heart Assoc; 2019 Jan; 8(2):e010956. PubMed ID: 30636561
[TBL] [Abstract][Full Text] [Related]
4. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
[TBL] [Abstract][Full Text] [Related]
5. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
[TBL] [Abstract][Full Text] [Related]
6. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
[TBL] [Abstract][Full Text] [Related]
7. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
[TBL] [Abstract][Full Text] [Related]
8. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
9. Randomized Comparison of Intensified and Standard P2Y
Mehilli J; Baquet M; Hochholzer W; Mayer K; Tesche C; Aradi D; Xu Y; Thienel M; Gschwendtner S; Zadrozny M; Jochheim D; Sibbing D; Schüpke S; Mansmann U; Hoffmann E; Kastrati A; Neumann FJ; Massberg S
Circ Cardiovasc Interv; 2020 Jun; 13(6):e008649. PubMed ID: 32527192
[TBL] [Abstract][Full Text] [Related]
10. Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Shoji S; Sawano M; Sandhu AT; Heidenreich PA; Shiraishi Y; Ikemura N; Ueno K; Suzuki M; Numasawa Y; Fukuda K; Kohsaka S
JAMA Netw Open; 2020 Apr; 3(4):e202004. PubMed ID: 32239221
[TBL] [Abstract][Full Text] [Related]
11. Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Wiviott SD; Braunwald E; McCabe CH; Montalescot G; Ruzyllo W; Gottlieb S; Neumann FJ; Ardissino D; De Servi S; Murphy SA; Riesmeyer J; Weerakkody G; Gibson CM; Antman EM;
N Engl J Med; 2007 Nov; 357(20):2001-15. PubMed ID: 17982182
[TBL] [Abstract][Full Text] [Related]
12. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
[TBL] [Abstract][Full Text] [Related]
13. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry.
Zanchin T; Temperli F; Karagiannis A; Zanchin C; Räsänen M; Koskinas KC; Stortecky S; Hunziker L; Praz F; Blöchlinger S; Moro C; Moschovitis A; Seiler C; Billinger M; Heg D; Pilgrim T; Valgimigli M; Windecker S; Räber L
Circ Cardiovasc Interv; 2018 May; 11(5):e006132. PubMed ID: 29748219
[TBL] [Abstract][Full Text] [Related]
14. Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.
De Luca G; Verdoia M; Savonitto S; Ferri LA; Piatti L; Grosseto D; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Antonicelli R; Rogacka R; De Servi S;
Nutr Metab Cardiovasc Dis; 2020 May; 30(5):730-737. PubMed ID: 32127336
[TBL] [Abstract][Full Text] [Related]
15. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
Bundhun PK; Huang F
BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel Versus Ticagrelor in Patients With Acute Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Multicenter Randomized PRAGUE-18 Study.
Motovska Z; Hlinomaz O; Miklik R; Hromadka M; Varvarovsky I; Dusek J; Knot J; Jarkovsky J; Kala P; Rokyta R; Tousek F; Kramarikova P; Majtan B; Simek S; Branny M; Mrozek J; Cervinka P; Ostransky J; Widimsky P;
Circulation; 2016 Nov; 134(21):1603-1612. PubMed ID: 27576777
[TBL] [Abstract][Full Text] [Related]
17. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
[TBL] [Abstract][Full Text] [Related]
19. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.
Gimbel M; Qaderdan K; Willemsen L; Hermanides R; Bergmeijer T; de Vrey E; Heestermans T; Tjon Joe Gin M; Waalewijn R; Hofma S; den Hartog F; Jukema W; von Birgelen C; Voskuil M; Kelder J; Deneer V; Ten Berg J
Lancet; 2020 Apr; 395(10233):1374-1381. PubMed ID: 32334703
[TBL] [Abstract][Full Text] [Related]
20. Multicenter research of bleeding risk between prasugrel and clopidogrel in Japanese patients with coronary artery disease undergoing percutaneous coronary intervention.
Tokimasa S; Kitahara H; Nakayama T; Fujimoto Y; Shiba T; Shikama N; Nameki M; Himi T; Fukushima KI; Kobayashi Y
Heart Vessels; 2019 Oct; 34(10):1581-1588. PubMed ID: 30944971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]